The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
LGC to Increase Interest in Australian Medical Cannabis Company
Jan. 22, 2018 09:28AM PST
Cannabis Investing NewsLGC Capital announced a Binding Term Sheet with Habi Pharma, an Australian licensed cannabis company engaged with Little Green Pharma. As part of the deal, LGC’s strategic interest in Little Green Pharma will increase from 11.91 percent to 14.99 percent.
LGC Capital (TSXV:LG) announced a Binding Term Sheet with Habi Pharma, an Australian licensed cannabis company engaged with Little Green Pharma. As part of the deal, LGC’s strategic interest in Little Green Pharma will increase from 11.91 percent to 14.99 percent.
As quoted in the press release:
The proposed increase to 14.99% will take LGC’s interest in Little Green Pharma to just below the 15% threshold requiring approval from the Australian Foreign Investment Review Board.
Increasing LGC’s interest in Little Green Pharma has been a top priority for LGC over the past few months, and even more so since the Australian Government announced on January 4, 2018 an important step for the development of the Australian medical cannabis sector by permitting the export of medicinal cannabis products from Australia.
John McMullen, CEO of LGC commented, “The recent changes in Australian Government policy to allow companies like Little Green Pharma to export medical cannabis outside of Australia significantly changes the importance of this investment within the LGC global footprint portfolio.”
Click here to read the full press release.
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.